CLL patients: GIVe me three!

In this issue of Blood, Huber et al present a 3-year follow-up analysis of the phase 2 CLL2-GIVe trial, demonstrating continued robust clinical activity of the triplet combination of obinutuzumab, ibrutinib, and venetoclax in previ-ously untreated patients with del(17p) and/or TP53-mutated chronic lym-phocytic leukemia (CLL).

Automated summary

The study demonstrates the continued robust clinical activity of the triplet combination of obinutuzumab, ibrutinib, and venetoclax in previously untreated CLL patients with del(17p) and/or TP53 mutations.